The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, M.
Right arrow Articles by Man, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, M.
Right arrow Articles by Man, S.
The Journal of Immunology, 2001, 167: 5420-5428.
Copyright © 2001 by The American Association of Immunologists

Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E61

Mererid Evans*, Leszek K. Borysiewicz*, Alan S. Evans{dagger}, Martin Rowe*, Matthew Jones*, Uzi Gileadi{ddagger}, Vincenzo Cerundolo{ddagger} and Stephen Man2,*

* Department of Medicine, University of Wales College of Medicine and {dagger} Department of Obstetrics and Gynecology, University Hospital of Wales, Heath Park, Cardiff, United Kingdom; and {ddagger} Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom

Human papillomavirus (HPV) infection, particularly type 16, is causally associated with the development of cervical cancer. The E6 and E7 proteins of HPV are constitutively expressed in cervical carcinoma cells making them attractive targets for CTL-based immunotherapy. However, few studies have addressed whether cervical carcinomas can process and present HPV E6/E7-derived Ags for recognition by CTL. We generated HLA-A*0201-restricted CTL clones against HPV16 E629–38 that recognized HPV16 E6 Ags transfected into B lymphoblastoid cells. These CTL were unable to recognize HLA-A*0201+ HPV16 E6+ cervical carcinoma cell lines even when the level of endogenous HPV16 E6 in these cells was increased by transfection. This defect in presentation of HPV16 E629–38 correlated with low level expression of HLA class I, proteasome subunits low molecular mass protein 2 and 7, and the transporter proteins TAP1 and TAP2 in the cervical carcinoma cell lines. The expression of all of these proteins could be up-regulated by IFN-{gamma}, but this was insufficient for CTL recognition unless the level of HPV16 E6 Ag was also increased by transfection. CTL recognition of the HPV16 E629–38 epitope in 721.174 B cells was dependent on TAP expression but independent of immunoproteasome expression. Collectively, these findings suggest that presentation of the HPV16 E629–38 epitope in cervical carcinoma cell lines is limited both by the level of TAP expression and by the low level or availability of the source HPV E6 oncoprotein. These observations place constraints on the use of this, and potentially other, HPV-derived CTL epitopes for the immunotherapy of cervical cancer.




This article has been cited by other articles:


Home page
 Int ImmunolHome page
L. E. M. Oosten, D. Koppers-Lalic, E. Blokland, A. Mulder, M. E. Ressing, T. Mutis, A. G. S. van Halteren, E. J. H. J. Wiertz, and E. Goulmy
TAP-inhibiting proteins US6, ICP47 and UL49.5 differentially affect minor and major histocompatibility antigen-specific recognition by cytotoxic T lymphocytes
Int. Immunol., September 1, 2007; 19(9): 1115 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. H. van der Burg, S. J. Piersma, A. de Jong, J. M. van der Hulst, K. M. C. Kwappenberg, M. van den Hende, M. J. P. Welters, J. J. Van Rood, G. J. Fleuren, C. J. M. Melief, et al.
Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens
PNAS, July 17, 2007; 104(29): 12087 - 12092.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
K. M. E. Gallagher and S. Man
Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women
J. Gen. Virol., May 1, 2007; 88(5): 1470 - 1478.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Albers, K. Abe, J. Hunt, J. Wang, A. Lopez-Albaitero, C. Schaefer, W. Gooding, T. L. Whiteside, S. Ferrone, A. DeLeo, et al.
Antitumor Activity of Human Papillomavirus Type 16 E7-Specific T Cells against Virally Infected Squamous Cell Carcinoma of the Head and Neck
Cancer Res., December 1, 2005; 65(23): 11146 - 11155.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
K. L. Smith, A. Tristram, K. M. Gallagher, A. N. Fiander, and S. Man
Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18
Int. Immunol., February 1, 2005; 17(2): 167 - 176.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. C. Hill, S. J. Youde, S. Man, G. R. Teale, A. J. Baxendale, A. Hislop, C. C. Davies, D. M. Luesley, A. M. Blom, A. B. Rickinson, et al.
Activation of CD40 in Cervical Carcinoma Cells Facilitates CTL Responses and Augments Chemotherapy-Induced Apoptosis
J. Immunol., January 1, 2005; 174(1): 41 - 50.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. Nardelli-Haefliger, D. Wirthner, J. T. Schiller, D. R. Lowy, A. Hildesheim, F. Ponci, and P. De Grandi
Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles
J Natl Cancer Inst, August 6, 2003; 95(15): 1128 - 1137.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2001 by The American Association of Immunologists, Inc. All rights reserved.